Bandaram Pharma

Market Cap: Micro Cap
Industry: Healthcare Services
ISIN: INE875N01036
NSEID:
BSEID: 524602
View on BSE

INR

28.10

0.57 (2.07%)

BSENSE

Jun 10, 02:15 PM

BSE+NSE Vol: 160

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shree Pacetronix

Bandaram Pharma

Deccan Healthcar

Choksi Laborator

N G Industries

Modern Diagnost.

Royal Sense

Amkay Products

KMS Medisurgi

Samsrita Labs

Invicta Diagnos.

Why is Bandaram Pharma Packtech Ltd ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.33%

Low ability to service debt as the company has a high Debt to EBITDA ratio of 8.23 times

Below par performance in long term as well as near term

Along with generating -26.25% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Healthcare Services)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Bandaram Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Bandaram Pharma

-26.25%

-0.38

69.49%

Sensex

-10.08%

-0.74

13.06%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

35.44%

EBIT Growth (5y)

32.07%

EBIT to Interest (avg)

1.54

Debt to EBITDA (avg)

7.75

Net Debt to Equity (avg)

0.87

Sales to Capital Employed (avg)

1.21

Tax Ratio

31.17%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

4.85%

ROE (avg)

4.21%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

152

Industry P/E

Price to Book Value

1.88

EV to EBIT

32.69

EV to EBITDA

25.27

EV to Capital Employed

1.47

EV to Sales

1.17

PEG Ratio

Dividend Yield

0.05%

ROCE (Latest)

4.50%

ROE (Latest)

1.23%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

NET SALES(Latest six months)

Higher at Rs 41.10 cr

PAT(Latest six months)

Higher at Rs 0.28 cr

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Bandaram Pharma

Net Sales - Quarterly

At Rs 26.26 cr has Grown at 209.31%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months

Higher at Rs 0.28 cr

than preceding 12 month period ended Mar 2026 of Rs 0.19 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Net Sales - Quarterly

Highest at Rs 26.26 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)